Stockscreener 앱 받기
38.37
0.52%
0.1754
전일 마감가:
$38.19
열려 있는:
$37.83
하루 거래량:
60,407
Relative Volume:
0.04
시가총액:
$4.60B
수익:
$18.47M
순이익/손실:
$-589.53M
주가수익비율:
-7.2938
EPS:
-5.26
순현금흐름:
$-399.80M
1주 성능:
+2.86%
1개월 성능:
+3.25%
6개월 성능:
-19.10%
1년 성능:
-31.26%
1일 변동 폭
$37.76
$38.44
1주일 범위
$36.77
$39.14
52주 변동 폭
$29.31
$59.39
Cytokinetics Inc Stock (CYTK) Company Profile
명칭
Cytokinetics Inc
전화
(650) 624-3000
주소
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
CYTK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
38.43 | 4.43B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
388.86 | 99.72B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
595.39 | 60.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.41 | 58.15B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
705.55 | 41.45B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.75 | 36.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 재개 | Raymond James | Mkt Perform |
| 2025-04-24 | 개시 | Barclays | Overweight |
| 2025-02-07 | 개시 | Citigroup | Buy |
| 2025-01-22 | 개시 | Stifel | Buy |
| 2024-11-08 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-07 | 개시 | B. Riley Securities | Buy |
| 2023-08-15 | 개시 | SVB Securities | Outperform |
| 2023-02-17 | 개시 | BofA Securities | Neutral |
| 2022-12-23 | 재확인 | Needham | Buy |
| 2022-12-20 | 개시 | Truist | Buy |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-01-28 | 개시 | Goldman | Buy |
| 2021-12-22 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | JP Morgan | Overweight |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2021-02-18 | 개시 | Barclays | Overweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-29 | 개시 | Goldman | Neutral |
| 2020-07-10 | 개시 | Raymond James | Strong Buy |
| 2020-05-05 | 개시 | Mizuho | Buy |
| 2020-04-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 재개 | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 재확인 | Morgan Stanley | Overweight |
| 2017-11-22 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2017-11-21 | 재확인 | H.C. Wainwright | Buy |
| 2017-07-31 | 개시 | Morgan Stanley | Overweight |
| 2017-03-08 | 개시 | Rodman & Renshaw | Buy |
| 2017-02-06 | 업그레이드 | Needham | Buy → Strong Buy |
| 2016-12-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 재확인 | Needham | Buy |
| 2015-11-10 | 재확인 | FBR Capital | Outperform |
| 2015-11-09 | 재확인 | ROTH Capital | Buy |
| 2015-07-24 | 재확인 | MLV & Co | Buy |
| 2014-12-31 | 재확인 | ROTH Capital | Buy |
| 2014-11-04 | 업그레이드 | MLV & Co | Hold → Buy |
| 2014-04-28 | 재확인 | Needham | Buy |
모두보기
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Cytokinetics Stock Price, Quotes and Forecasts | NASDAQ:CYTK - Benzinga
Pattern recognition hints at Cytokinetics Incorporated upsideWeekly Profit Analysis & Weekly Market Pulse Alerts - Newser
Should you hold or exit Cytokinetics Incorporated nowPortfolio Performance Report & Verified Chart Pattern Signals - Newser
Risk adjusted return profile for Cytokinetics Incorporated analyzedJuly 2025 Big Picture & Weekly Top Gainers Alerts - Newser
How to manage a losing position in Cytokinetics IncorporatedRisk Management & Weekly Chart Analysis and Trade Guides - Newser
What the charts say about Cytokinetics Incorporated todayJuly 2025 Rallies & Real-Time Market Trend Scan - Newser
Multi asset correlation models including Cytokinetics IncorporatedPortfolio Return Summary & Long-Term Capital Growth Ideas - Newser
What moving averages say about Cytokinetics IncorporatedJuly 2025 PreEarnings & Growth Focused Entry Point Reports - Newser
Cytokinetics Incorporated stock volume spike explained2025 Top Gainers & High Yield Stock Recommendations - Newser
What data driven models say about Cytokinetics Incorporated’s futureWeekly Trade Report & Community Consensus Picks - Newser
Visualizing Cytokinetics Incorporated stock with heatmapsPortfolio Risk Summary & Fast Entry Momentum Alerts - Newser
Cytokinetics Incorporated stock chart pattern explainedQuarterly Profit Report & Accurate Technical Buy Alerts - Newser
Cytokinetics Incorporated stock retracement – recovery analysisLong Setup & Weekly Return Optimization Plans - Newser
What’s next for Cytokinetics Incorporated stock priceShort Setup & Real-Time Chart Breakout Alerts - Newser
Shareholder Rights Advocates at Levi & Korsinsky Investigate Cytokinetics, Incorporated (CYTK) Regarding Possible Securities Fraud Violations - ACCESS Newswire
When is the best time to exit Cytokinetics IncorporatedWeekly Trend Recap & Comprehensive Market Scan Insights - Newser
Can Cytokinetics Incorporated rally from current levelsJuly 2025 Volume & Fast Gain Swing Trade Alerts - Newser
Cytokinetics to Present Positive Aficamten Results at ESC Congress 2025 with Investor Webcast Scheduled for September 2, 2025 - Quiver Quantitative
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025 - Yahoo Finance
Has Cytokinetics Incorporated formed a bullish divergenceJuly 2025 Earnings & Reliable Momentum Entry Alerts - Newser
Live Scanner Shows Breakout on Cytokinetics IncorporatedWall Street Watch & Community Driven Trade Alerts - 더경남뉴스
Sentiment analysis tools applied to Cytokinetics IncorporatedTrade Analysis Summary & Safe Capital Allocation Plans - Newser
Cytokinetics Appoints James M. Daly to Board of Directors - AInvest
Cytokinetics shares fall 1.35% intraday after appointing Jim Daly to Board of Directors. - AInvest
Acadian Asset Management Inc. shares fall 1.42% intraday after Cytokinetics appoints Jim Daly to Board of Directors. - AInvest
Cytokinetics Appoints James M. Daly to Board - TipRanks
Cytokinetics: Specialty Franchise With Aficamten And Ulacamten (NASDAQ:CYTK) - Seeking Alpha
Cytokinetics Names Jim Daly to Board of Directors - The Globe and Mail
Cytokinetics appoints James Daly to board of directors - Investing.com
Cytokinetics Appoints James Daly to Board with Commercialization Expertise. - AInvest
How to use Fibonacci retracement on Cytokinetics IncorporatedWeekly Trading Summary & Real-Time Volume Trigger Notifications - Newser
Will breakout in Cytokinetics Incorporated lead to full recovery2025 Price Targets & Community Consensus Picks - Newser
Cytokinetics Inc Announces Stock Options and RSUs for New Employees Amid Ongoing Cardiovascular Advancements - AInvest
How Efficient Is Cytokinetics Incorporated at Controlling Operating Costs2025 Price Momentum & Risk Managed Trade Strategies - Newser
Cytokinetics EVP Malik sells $76k in shares - Investing.com
Cytokinetics EVP Malik sells $76k in shares By Investing.com - Investing.com UK
Cytokinetics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
105,169 Stock Options at $38.67: Cytokinetics Issues Major Employee Inducement Grants - Stock Titan
Cytokinetics Incorporated Inches Above Key Support — Safe to Hold2025 Volatility Report & High Return Trade Guides - 선데이타임즈
Will Cytokinetics Incorporated Recover After Recent DeclineJuly 2025 Analyst Calls & AI Driven Stock Movement Reports - newsimpact.co.kr
Is Cytokinetics Incorporated stock entering bullish territoryQuarterly Trade Report & Precise Swing Trade Alerts - Newser
What to expect from Cytokinetics Incorporated in the next 30 daysSell Signal & Verified Stock Trade Ideas - Newser
Using Ichimoku Cloud for Cytokinetics Incorporated technicalsQuarterly Profit Report & High Conviction Buy Zone Alerts - Newser
Is Cytokinetics Incorporated’s ROE strong enoughJuly 2025 Pullbacks & Free High Return Stock Watch Alerts - thegnnews.com
Relative strength of Cytokinetics Incorporated in sector analysisPortfolio Risk Report & Intraday High Probability Alerts - Newser
What candlestick patterns are forming on Cytokinetics IncorporatedPortfolio Return Report & Weekly Market Pulse Updates - Newser
Why Cytokinetics Incorporated stock attracts strong analyst attention2025 Major Catalysts & Real-Time Sentiment Analysis - Newser
Cytokinetics (CYTK) Receives Buy Rating from Mizuho Securities with $84 Price Target - AInvest
Cytokinetics CEO Cashes In on Stock Sale - TipRanks
Citi Lowers Cytokinetics (CYTK) PT to $77 Due to Uneventful Q2 2025 Earnings - MSN
Cytokinetics Inc (CYTK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cytokinetics Inc 주식 (CYTK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Aug 19 '25 |
Sale |
38.31 |
2,000 |
76,620 |
140,610 |
| Blum Robert I | President & CEO |
Aug 15 '25 |
Sale |
38.42 |
5,000 |
192,100 |
383,108 |
| Malik Fady Ibraham | EVP Research & Development |
Aug 05 '25 |
Option Exercise |
10.60 |
2,000 |
21,200 |
142,610 |
| Malik Fady Ibraham | EVP Research & Development |
Aug 05 '25 |
Sale |
36.34 |
2,000 |
72,680 |
140,610 |
| Blum Robert I | President & CEO |
Jul 29 '25 |
Sale |
36.45 |
5,000 |
182,250 |
388,108 |
| Malik Fady Ibraham | EVP Research & Development |
Jul 22 '25 |
Option Exercise |
10.60 |
2,000 |
21,200 |
142,610 |
| Malik Fady Ibraham | EVP Research & Development |
Jul 22 '25 |
Sale |
37.47 |
2,000 |
74,940 |
140,610 |
| Blum Robert I | President & CEO |
Jul 14 '25 |
Sale |
38.15 |
5,000 |
190,750 |
393,108 |
1.46%
6.57%
자본화:
|
볼륨(24시간):